EICOSANOIDS--OCULAR PHYSIOLOGY AND PHARMACOLOGY

一些类二十烷酸（ED），如野牡丹素及其衍生物， 在所有研究的动物中均显示为有效的眼部消肿剂 以及血压正常的人类志愿者。 然而，ED，像其他 药物，有副作用，除非它们可以减少或消除， 可能限制这些物质在长期临床中的有用性 治疗慢性肿瘤。 该项目的目标是获得一个 明确了解ED的眼部效应机制， 提供ED发展所需的基本信息， 长期维持IOP降低的有效药物， 眼部和全身副作用。 我们将进行彻底的 研究以下特定领域：1）眼部 ED的药代动力学将特别参考 正射校正缓释系统，使用体内示踪剂技术和 体外流量研究; 2）ED诱导的IOP降低机制的研究 将包括分泌物、假性设施、常规和葡萄膜巩膜 流出，使用荧光光度计，同位素稀释，张力描记术， 灌注技术。 3)其他眼部影响的机制将是 研究，包括瞳孔缩小（瞳孔造影，艾德对离体虹膜的影响 肌肉）和结膜充血（示踪研究），以及崩溃 血-水屏障（测量廷德尔效应和蛋白质 在爆发的种属（猫、灵长类动物和兔）中， 发展到不同的程度。 基本了解 ED的药代动力学、作用机制和副作用将 提供有效使用眼保健品所必需的信息 眼科医生进行的急诊室检查用于临床管理 昏迷。 这种理解对于审议《公约》也是必不可少的。 的ED在其他领域的眼科治疗和发展， 第二代和第三代青光眼药物。 这种可能性仍然存在 然而，在血压正常的患者中，有效降低IOP的ED 人类受试者对青光眼眼睛没有相同的效果。 如果这 事实证明，我们的研究将作出重要贡献 对青光眼的理解，因为这种缺乏效果意味着， 青光眼与青光眼的艾德系统的某些方面的缺陷有关。 前节。 简而言之，这种多管齐下的方法将使 对眼科研究和青光眼研究的重要贡献 特别是，我们相信，执行主任是否会提供 青光眼治疗的新方法

Some eicosanoids (EDs), such as prostaglandins and their derivatives, have been shown to be effective ocular hypotensive agents in all animals studied as well as in normotensive human volunteers. However, EDs, like other drugs, have side effects which, unless they can be reduced or eliminated, may limit the usefulness of these substances in the long-term clinical management of chronic glaucomas. The goal of this project is to gain a clear understanding of the mechanisms of the ocular effects of EDs in order to provide the basic information required for the development of EDs as effective drugs for the long-term maintenance of IOP reduction with minimal ocular and systemic side effects. We shall undertake a thorough investigation of the following specific areas: 1) The ocular pharmacokinetics of EDs will be studied with special reference to an orthorectified slow-release system, using in vivo tracer techniques and in vitro flux studies; 2) studies on the mechanism of ED-induced IOP reduction will include secretion, pseudofacility, and conventional and uveoscleral outflow, using fluorophotometry, isotope dilution, tonography, and perfusion techniques. 3) The mechanism of other ocular effects will be studied, including miosis (pupillography, ED effects on isolated iridial muscles) and conjunctival hyperemia (tracer studies), as well as breakdown of the blood aqueous barrier (measurement of Tyndall effect and protein concentration) in species (cats, primates, and rabbits) in which flare develops to greatly different extents. A basic understanding of the pharmacokinetics, mechanisms of action, and side effects of EDs will provide the information essential for the effective use of ocular hypotensive EDs by ophthalmologists for the clinical management of glaucomas. Such understanding will also be essential for the consideration of EDs in other areas of ocular therapeutics and for the development of second and third generations of glaucoma drugs. The possibility still exists, however, that EDs, which effectively reduce IOP in normotensive human subjects, do not have the same effect on glaucomatous eyes. If this proves to be the case, our studies will make an important contribution to the understanding of glaucoma, since such lack of effect would imply that glaucoma is associated with a defect in some aspects of the ED system of the anterior segment. In short, this multipronged approach will make an important contribution to eye research in general and to glaucoma research in particular whether or not EDs do, as we believe that they will, provide a new approach to the medical management of glaucoma.